<!DOCTYPE html>
<html class="no-js" lang="en" dir="ltr">

<head>
    <meta charset="utf-8">
<meta content="width=device-width,initial-scale=1" name="viewport">
	<link rel="schema.dcterms" href="http://purl.org/dc/terms/">	
		<meta name="description" content="Information about any adverse events following immunization (AEFI) that individuals have reported after receiving a COVID-19 vaccine in Canada. These adverse events are not necessarily related to the vaccine.">	
		<meta name="keywords" content="coronavirus, covid-19, pandemic, Canada, vaccines covid, vaccines canada, vaccines covid, coronavirus vaccines, safety, side effects, adverse reaction, AEFI">	
		<meta name="author" content="Public Health Agency of Canada">	
		<meta name="dcterms.title" content="COVID-19 vaccine safety: Weekly report on side effects following immunization">	
		<meta name="dcterms.description" content="Information about any adverse events following immunization (AEFI) that individuals have reported after receiving a COVID-19 vaccine in Canada. These adverse events are not necessarily related to the vaccine.">	
		<meta name="dcterms.creator" content="Public Health Agency of Canada">	
		<meta name="dcterms.language" title="ISO639-2/T" content="eng">
		<meta name="dcterms.subject" title="gccore" content="HE Health and Safety">	
		<meta name="dcterms.issued" title="W3CDTF" content="2021-01-08">	
		<meta name="dcterms.modified" title="W3CDTF" content="2021-01-29">	
		<meta name="dcterms.spatial" content="Canada">	
		<meta name="dcterms.type" content="datasets;statistics;education and awareness">	
		<meta name="dcterms.source" content="aem">	
		<meta name="dcterms.identifier" content="Public_Health_Agency_of_Canada">
		<meta prefix="fb: https://www.facebook.com/2008/fbml" property="fb:pages" content="378967748836213, 160339344047502, 184605778338568, 237796269600506, 10860597051, 14498271095, 209857686718, 160504807323251, 111156792247197, 113429762015861, 502566449790031, 312292485564363, 1471831713076413, 22724568071, 17294463927, 1442463402719857, 247990812241506, 730097607131117, 1142481292546228, 1765602380419601, 131514060764735, 307780276294187, 427238637642566, 525934210910141, 1016214671785090, 192657607776229, 586856208161152, 1146080748799944, 408143085978521, 490290084411688, 163828286987751, 565688503775086, 460123390028, 318424514044, 632493333805962, 370233926766473, 173004244677, 1562729973959056, 362400293941960, 769857139754987, 167891083224996, 466882737009651, 126404198009505, 135409166525475, 664638680273646, 169011506491295, 217171551640146, 182842831756930, 1464645710444681, 218822426028, 218740415905, 123326971154939, 125058490980757, 1062292210514762, 1768389106741505, 310939332270090, 285960408117397, 985916134909087, 655533774808209, 1522633664630497, 686814348097821, 230798677012118, 320520588000085, 103201203106202, 273375356172196, 61263506236, 353102841161, 1061339807224729, 1090791104267764, 395867780593657, 1597876400459657, 388427768185631, 937815283021844, 207409132619743, 1952090675003143, 206529629372368, 218566908564369, 175257766291975, 118472908172897, 767088219985590, 478573952173735, 465264530180856, 317418191615817, 428040827230778, 222493134493922, 196833853688656, 194633827256676, 252002641498535, 398018420213195, 265626156847421, 202442683196210, 384350631577399, 385499078129720, 178433945604162, 398240836869162, 326182960762584, 354672164565195, 375081249171867, 333050716732105, 118996871563050, 240349086055056, 119579301504003, 185184131584797, 333647780005544, 306255172770146, 369589566399283, 117461228379000, 349774478396157, 201995959908210, 307017162692056, 145928592172074, 122656527842056">

    <title>COVID-19 vaccine safety: Weekly report on side effects following immunization - Canada.ca</title>
   
	<link rel="apple-touch-icon" sizes="57x57 72x72 114x114 144x144 150x150" class="wb-favicon" href="/src/GCWeb/assets/favicon-mobile.png"><link href="/src/GCWeb/assets/favicon.ico" rel="icon" type="image/x-icon" class="wb-init wb-favicon-inited">

    <link href="/src/GCWeb/assets/favicon.ico" rel="icon" type="image/x-icon">
    <link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.12.0/css/all.css" integrity="sha384-REHJTs1r2ErKBuJB0fCK99gCYsVjwxHrSU0N7I1zl9vZbggVJXRMsv/sLlOAGb4M" crossorigin="anonymous">
    <link rel="stylesheet" href="/src/GCWeb/css/wet-boew.min.css">
    <link rel="stylesheet" href="/src/GCWeb/css/theme.min.css">

    <noscript><link rel="stylesheet" href="/src/wet-boew/css/noscript.min.css" /></noscript>

    <style type="text/css">
        #bigGraph{
            font-size:0.7em;
        }
            .circle {
            display: inline-block;
            float: left;
            width: 15px;
            height: 15px;
            border-radius: 50%;
            margin: 0 5px;
            position: absolute;
            top: 50%;
            transform: translate(0, -50%);
        }

        .selection {
            -webkit-user-select: none;
            /* Safari */
            -moz-user-select: none;
            /* Firefox */
            -ms-user-select: none;
            /* IE10+/Edge */
            user-select: none;
            /* Standard */
            margin: 0 1px;
            position: relative;
            width: 150px;
            height: 40px;
            font-size: 1em;
            border: solid 2px rgba(150, 150, 150, 0.2);
            cursor: pointer;
        }

        .selection p {
            line-height: 20px;
            margin-left: 22px;
            display: inline;
            position: absolute;
            top: 50%;
            transform: translate(0, -50%);
        }

        .selection:hover {
            background-color: rgba(150, 150, 150, 0.2);
        }

        #displayPanel {
            width: 100%;
            display: -ms-grid;
            display: grid;
            -ms-grid-columns: 150px 1fr;
            grid-template-columns: 150px auto;
        }

        #logPanel {
            -ms-grid-column: 1;
            -ms-grid-row: 1;
            padding-bottom: 5px;
            width: 100%;
            display: flex;
            justify-content: space-evenly;
        }

        #logPanel button {
            height: 35px;
            margin: 0;
        }

        #descPanel {
            -ms-grid-column: 2;
            -ms-grid-row: 1;
        }

        #descPanel p {
            line-height: 20px;
            font-size:0.9em;
            margin:0;
            text-align: center;
        }

        #descPanel span {
            font-weight: bold;
        }

        #btnPanel {
        -ms-grid-column-span:2;
        -ms-grid-row:3;
        grid-column: span 2;
            padding: 0;
            width: 100%;
            display: flex;
            flex-wrap: wrap;
            justify-content: center;
        }

        #graphPanel {
                -ms-grid-column:1;
            -ms-grid-column-span:2;
            -ms-grid-row:2;
            grid-column: span 2;
            grid-row: 2/3;
            width: 100%;
        }

        #big {
            width: 100%;
            height: 300px;
        }

        #big .tick text {
            font-size: 1.1em;
        }

        .tab {
            overflow: hidden;
            background-color: white;
            color: #295376;
        }

        /* Style the buttons inside the tab */

        .tab button {
            background-color: inherit;
            /*float: left;*/
            border: none;
            outline: none;
            cursor: pointer;
            padding: 2px 16px;
            transition: 0.3s;
            font-size: 17px;
            color: #295376;
        }

        /* Change background color of buttons on hover */

        .tab button:hover {
            background-color: #ddd;
        }

        .tab button:focus {
            border: 1px solid black;
        }

        /* Create an active/current tablink class */

        .tab button.active {
            background-color: #ccc;
        }

        /* Style the tab content */

        .tabcontent {
            display: none;
            padding: 6px 12px;
            border-top: none;
        }

        .bar {
            fill: #015B7E;
            stroke: #015B7E;
        }

        .axis {
            stroke: #D8D8D8;
        }

        text {
            /* fill: #6c686f; */
            fill: black;
        }

        .tick>line,
        .domain {
            stroke: #ccc;
        }

        .x-axis-title,
        .y-axis-title {
            font-size: 0.8em;
        }

        .x-axis .tick line {
            stroke: black;
        }

        .x-axis,
        .y-axis {
            font-size: 12px;
        }

        label {
            display: inline;
        }

        .line {
            fill: none;
            stroke-width: 3px;
        }

        .chart rect {
            stroke: black;
            stroke-width: 0.09px;
        }
        
        /*dashboard */
        #dashboard {
            /*height: 90%;*/
        }
        
        /* Key numbers boxes */
        .boxes {
            text-align: center;
            display: flex;
            flex-wrap: wrap;
            padding-left: 1px;
            padding-right: 1px;
            height: 10%;
            justify-content: center;
        }


        .boxes a, .boxes a:visited, .boxes a:focus {
            flex: 0 0 30%;    
            border: 3px solid #ccc;
            border-radius: 10px;
            margin: 10px;
            text-decoration: none;
            color: black;
        }
        .boxes a:hover {
            border: 3px solid #000;
            border-radius: 10px;
            box-shadow: 2px 2px;
        }
        
        .innerBox {
            flex: 0 0 23%;
            border: 1px solid #ccc;
            border-radius: 10px;
            margin-left: 0px;
            margin-right: 3px;
            text-decoration: none;
            color: black;
            margin-bottom: 5px;
        }
        .innerBox div {
            padding-left: 3px;
            padding-right: 3px;
        }

        .boxes p {
            font-size: 18px;
            margin-top: 5px;
            margin-bottom: 5px;
        }

        .boxes p.h2 {
            font-size: 30px;
            margin-top: 5px;
        }
        table {
            border: 1.5px solid black;
        }
        td {
            border: 1.5px solid black;
            padding: 4px;
        }
        th {
            border: 1.5px solid black;
            padding: 5px;
        }
        .figureTable td {
            border: 1.5px solid black;
            padding: 0px;
            padding-left: 4px;
        }
        .figureTable th {
            border: 1.5px solid black;
            padding: 0px;
            padding-left: 4px;
            padding-right: 4px;
        }
        
        /*#box1 {*/
        /*    color: rgb(77, 140, 158);*/
        /*}*/

        /*#box2 {*/
        /*    color: rgb(216, 135, 46);*/
        /*}*/

        /*#box3 {*/
        /*    color: rgb(128, 155, 40);*/
        /*}*/

        /*#box4 {*/
        /*    color: rgb(84, 80, 134);*/
        /*}*/
        
        
        /* Graph Panels */
        #graphArea {
            /*text-align: center;*/
            display: flex;
            flex-wrap: wrap;
            justify-content: center;
            padding-left: 0px;
            padding-right: 0px;
        }
        .graphPanels {
            flex: 0 0 47%;
            margin: 10px;
            text-decoration: none;
            color: black;
            margin-bottom: 5px;
            padding-left: 10px;
            padding-right: 10px;
            border: 1px solid #ccc;
            border-radius: 10px;
        }
        
        
        #graphHospital text,
        #graphHospitalBySex text {
            font-size: 16px;
        }

        #probable-exposure .y-axis,
        #probable-exposure .x-axis,
        #probable-exposure #legend {
            font-size: 16px;
        }

        td#ratetested {
            min-width: 80px;
        }

        td#numtested {
            min-width: 113px;
        }
            
        #full:disabled{
          background-color: #cccccc;
        }

        @media only screen and (max-width: 800px) {

            #probable-exposure .y-axis,
            #probable-exposure .x-axis,
            #probable-exposure #legend {
                font-size: 18px;
            }

            #hospitalization text {
                font-size: 18px;
            }
            .x-axis-title,
            .y-axis-title {
                font-size: 1.1em!important;
            }
            .txtTotal {
                white-space: nowrap;
            }
            
            .boxes a:visited, .boxes a:focus, .boxes a:hover {
                flex: 0 0 37.5%;    
                border: 1px solid #ccc;
                border-radius: 10px;
                margin: 5px;
                text-decoration: none;
                color: black;
            }
            .boxes p{
                font-size: 16px;
            }
        }

        @media only screen and (max-width: 991px) {
            .selection {
                border-radius: 0;
            }
            #big {
                height: 500px;
            }
            #btnPanel {
                -ms-grid-column-span: 2;
                -ms-grid-row: 3;
                grid-column: span 2;
            }
            #graphPanel {
                -ms-grid-column: 1;
                -ms-grid-column-span: 2;
                -ms-grid-row: 2;
                grid-column: span 2;
                grid-row: 2/3;
            }
            #mainImg {
                margin-bottom: 20px;
            }
            .textarea {
                margin-top: 20px;
            }
                        #full, #howto {
                display:none;
            }
         .innerBox, .graphPanels {
             flex: 0 0 100%;
         }   
        }

        @media only screen and (min-width: 991px) {
            .pathText {
                display: none;
            }
            .textarea {
                margin-top: 128px;
                height: 138px;
            }
        }

        #graphHospitalBySex {
            display: none;
        }

        @media only screen and (max-width: 525px) {
            .selection {
                width: 180px;
                height: 50px;
            }
            .selection p {
                margin-left: 27px;
            }
            #big {
                height: 300px;
            }
            #descPanel {
                -ms-grid-column: 1;
                -ms-grid-column-span: 2;
                -ms-grid-row: 2;
                grid-column: span 2;
            }
            #logPanel {
                -ms-grid-column-span: 2;
                flex-wrap: wrap;
                grid-column: span 2;
            }
            #btnPanel {
                -ms-grid-row: 4;
            }
            #graphPanel {
                -ms-grid-row: 3;
                grid-column: span 2;
                grid-row: 3/4;
            }
            .btn-success,
            .btn-info {
                margin: 5px 0px!important;
                width: 100%!important;
            }
        }

        @media only screen and (max-width: 1690px)  {
            p.fsel, h3.fsel {
                font-size: 1.1vw!important;
            }
            
            h1.fsel{
                font-size: 2vw!important;
            }
            
            .innerBox.fsel{
                margin-left: 2px;
                margin-right: 2px;
            }
            
            #full.fsel, #howto.fsel, #langToggle.fsel{
                font-size: 0.8vw;
            }
            
            .graphPanels.fsel{
                /*height: 40%!important;*/
                /*flex: 0 0 46%!important;*/
                margin: 2px!important;
            }
            
            #barDiv.fsel .axis text, #barDiv.fsel .barText{
                font-size: 23px!important;
            }
            
            #trendData.fsel .trendX text,#trendData.fsel .trendY text,#trendData.fsel .xAxisTrendLabel,#trendData.fsel yAxisTrendLabel,#trendData2.fsel .trendX2 text,#trendData2.fsel .trendY2 text,#trendData2.fsel .xAxisTrendLabel2, yAxisTrendLabel2{
                font-size: 15px;
            }
            
            .graphPanelsText p.fsel{
                line-height: 3vh;
                font-size: 1.3vh!important;
            }
        }
        
        @media only screen and (max-width: 1200px)  {
            .dropdown {
                /*height: 29px !important;*/
                font-size: 0.9em !important;
            }
        }
        
        @media only screen and (max-width: 1000px)  {
            #full, #howto, #langToggle {
                margin-top:-10px !important;
            } 
        }
    	.navbuttons {
    	    padding:0px;
    	}
    	.navbuttons .btn-group{
    	    padding:20px 0px;
    	}
    	@media only screen and (max-width: 768px) {
    	    .boxes a, .boxes a:visited, .boxes a:focus, .boxes a:hover {
            flex: 0 0 100%;
            border: 3px solid #ccc;
            border-radius: 10px;
            margin: 10px;
            text-decoration: none;
            color: black;
    	    }
    	    .navbuttons a {
    	        padding:10px 0px !important;
    	        /*font-size:16px !important;*/
    	    }
    	}
    	
    </style>
</head>

<body vocab="http://schema.org/" typeof="WebPage">
    <!-- Google Tag Manager DO NOT REMOVE OR MODIFY - NE PAS SUPPRIMER OU MODIFIER -->
    <script>dataLayer1 = [];</script>
	<script>dataLayer = [];</script>
    <!-- End Google Tag Manager -->
    	<!-- Google Tag Manager -->
    <noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-TN3RPZ"
    height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
    })(window,document,'script','dataLayer','GTM-TN3RPZ');</script>
    <!-- End Google Tag Manager -->
    <!-- Google Tag Manager DO NOT REMOVE OR MODIFY - NE PAS SUPPRIMER OU MODIFIER -->
    <noscript><iframe title="Google Tag Manager" src="//www.googletagmanager.com/ns.html?id=GTM-TLGQ9K" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer1'?'&l='+l:'';j.async=true;j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer1','GTM-TLGQ9K');</script>
    <!-- End Google Tag Manager -->
    
    <ul id="wb-tphp">
        <li class="wb-slc">
            <a class="wb-sl" href="#wb-cont">Skip to main content</a>
        </li>
        <li class="wb-slc">
            <a class="wb-sl" href="#wb-info">Skip to "About government"</a>
        </li>
    </ul>
    <header>
        <div id="wb-bnr" class="container">
            <section id="wb-lng" class="text-right">
                <h2 class="wb-inv">Language selection</h2>
                <ul class="list-inline margin-bottom-none">
                    <li><a lang="fr" href="https://sante-infobase.canada.ca/covid-19/securite-vaccins/">Français</a></li>
                </ul>
            </section>
            <div class="row">
                <div class="brand col-xs-5 col-md-4">
                    <a href="https://www.canada.ca/en.html"><img src="/src/GCWeb/assets/sig-blk-en.svg" alt=""><span class="wb-inv"> Government of Canada / <span lang="fr">Gouvernement du Canada</span></span></a>
                </div>
                <section id="wb-srch" class="col-lg-8 text-right">
                    <h2>Search</h2>
                    <form action="https://www.canada.ca/en/sr/srb.html" method="get" name="cse-search-box" role="search" class="form-inline">
                        <div class="form-group">
                            <label for="wb-srch-q" class="wb-inv">Search Canada.ca</label>
                            <input id="wb-srch-q" list="wb-srch-q-ac" class="wb-srch-q form-control" name="q" type="search" value="" size="34" maxlength="170" placeholder="Search Canada.ca">
                            <datalist id="wb-srch-q-ac">
                            </datalist>
                        </div>
                        <div class="form-group submit">
                            <button type="submit" id="wb-srch-sub" class="btn btn-primary btn-small" name="wb-srch-sub"><span class="glyphicon-search glyphicon"></span><span class="wb-inv">Search</span></button>
                        </div>
                    </form>
                </section>
            </div>
        </div>
        <nav class="gcweb-menu" typeof="SiteNavigationElement">
            <div class="container">
                <h2 class="wb-inv">Menu</h2>
                <button type="button" aria-haspopup="true" aria-expanded="false"><span class="wb-inv">Main </span>Menu <span class="expicon glyphicon glyphicon-chevron-down"></span></button>
                <ul role="menu" aria-orientation="vertical" data-ajax-replace="/src/ajax/sitemenu-v2-en.html">
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/jobs.html">Jobs and the workplace</a></li>
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/immigration-citizenship.html">Immigration and citizenship</a></li>
                    <li role="presentation"><a role="menuitem" href="https://travel.gc.ca/">Travel and tourism</a></li>
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/business.html">Business and industry</a></li>
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/benefits.html">Benefits</a></li>
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/health.html">Health</a></li>
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/taxes.html">Taxes</a></li>
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/environment.html">Environment and natural resources</a></li>
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/defence.html">National security and defence</a></li>
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/culture.html">Culture, history and sport</a></li>
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/policing.html">Policing, justice and emergencies</a></li>
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/transport.html">Transport and infrastructure</a></li>
                    <li role="presentation"><a role="menuitem" href="http://international.gc.ca/world-monde/index.aspx?lang=eng">Canada and the world</a></li>
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/finance.html">Money and finances</a></li>
                    <li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/finance.html">Science and innovation</a></li>
                </ul>
            </div>
        </nav>
        <nav id="wb-bc" property="breadcrumb">
            <h2>You are here:</h2>
            <div class="container">
                <ol class="breadcrumb">
                    <li><a href="https://www.canada.ca/en.html">Canada.ca</a></li>
                    <li><a href="https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19.html">Coronavirus disease (COVID-19)</a></li>
                    <li><a href="https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19/vaccines.html">Vaccines for COVID-19</a></li>
                 </ol>
            </div>
        </nav>
    </header>
    <main property="mainContentOfPage" id="main" class="container">
            	<div id="surveyIframe" style="background-color:#335075;width:100%;height:150px;position:fixed;bottom:0px;left:0px;z-index:100;">
    		<button type="button" class="mfp-close overlay-close" title="Close overlay" style="">×<span class="wb-inv"> Close survey overlay</span></button>
    		<iframe src="https://ca1se.voxco.com/SE/?st=dgKt%2FuQTAgrMcyZdP0fuwOOo%2BQPsqhn%2B4rx9ZweEmF4%3D&lang=EN" height="150" width="100%" frameborder="0" scrolling="no" style="position:fixed;bottom:0px;z-index:100"></iframe>
        </div>
        
            <h1>Reported side effects following COVID-19 vaccination in Canada 
                <!--<a class="btn btn-info pull-right" href="#"><i class="fa fa-download" aria-hidden="true"></i> <span class="wb-invisible">Download page in </span>.pdf<span class="wb-invisible"> format</span></a>-->
            </h1>
        <!--<p>This page provides information about any adverse events that individuals have reported after receiving a COVID-19 vaccine in Canada. Even though an adverse event is reported, it is not necessarily related to the vaccine. We update this page every Friday at 12:00 PM Eastern Time. </p>-->
        <!--<p>Canada’s independent drug authorization process is known around the world for its high standards and rigorous review process. Decisions are based on scientific and medical evidence. Vaccines authorized for use in Canada are safe, effective and of high quality. </p>-->
        <!--<p>The work to make sure a vaccine is safe starts before the regulatory process even begins. Exploratory, preclinical studies, and clinical trials are designed to assess the vaccine’s safety. Evidence from these activities is submitted to Health Canada for regulatory review. Health Canada’s scientific and medical reviewers then conduct a thorough and independent review of all vaccine data. Only then is a vaccine authorized for use in Canada. Learn more about <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/development-approval-infographic.html">how vaccines are approved in Canada.</a></p>-->
        <!--<p>Some people have reported adverse events (side effects) after being immunized with a COVID-19 vaccine in Canada. These adverse events aren’t necessarily related to the vaccine. For example, they may be:</p>-->
        <!--<ul>-->
        <!--    <li>anxiety about immunization</li>-->
        <!--    <li>an allergic reaction to another substance</li>-->
        <!--    <li>related to a pre-existing condition</li>-->
        <!--    <li>coincidental</li>-->
        <!--</ul>-->
        <div class="col-md-12" style="padding: 0">
            <div class="btn-group btn-group-lg btn-group-justified" style="padding:20px 0px;">
                <a class="btn btn-default" role="button" href="summary.html">Summary</a>
                <a class="btn btn-primary active" role="button" href="/covid-19/vaccine-safety/">Weekly report</a>
                <!--<a class="btn btn-default" role="button" href="/covid-19/vaccine-safety/archive/">Archived reports</a>-->
            </div>
        </div>
        <p>We update this page every Friday at 12:00 PM Eastern Time. A <a href="summary.html">summary and background information</a> are available.</p>
        
        <p class="h3">This report was last updated on <span class="nowrap">June 11, 2021</span> with data up to and including <span class="dateToShort nowrap">MMM DD, YYYY</span>.</p>
        
        <h2>On this page</h2>
        <ul>
            <li><a href="#a1" class="anchor">What you need to know</a></li>
            <li><a href="#a2" class="anchor">Definitions</a></li>
            <li><a href="#howToReport" class="anchor">How to report an adverse event</a></li>
            <li><a href="#a3" class="anchor">Summary of adverse event following immunization reports </a></li>
            <li><a href="#a4" class="anchor">Adverse event following immunization reports by vaccine name</a></li>
            <li><a href="#a5" class="anchor">Adverse event following immunization reports by age and sex</a></li>
            <li><a href="#a6" class="anchor">Serious and non-serious adverse events reported</a></li>
            <li><a href="#specialInterest" class="anchor">Adverse events of special interest</a></li>
            <li><a href="#a7" class="anchor">Data notes</a></li>
            <li><a href="#acknowledgements" class="anchor">Acknowledgements</a></li>
            <li><a href="#citation" class="anchor">Suggested citation</a></li>
            <li><a href="#a8" class="anchor">Related links</a></li>
        </ul>
        <h2 id="a1">What you need to know <small><!--data reported--> up to and including <span class="dateToShort">MMM DD, 2021</span></small></h2>
        <!--<h3 id="updates" class="wb-inv">Key updates</h3>-->
        <!--<p>Weekly update as of <span class="dateToShort">MMM DD, 2021, TT:TTPM EDT</span></p>-->
        <div class='boxes'>
            <a href="#noteTTS" data-figure="1" class="anchor" style="display: flex; align-items: center;">
                <div class="mrgn-tp-lg mrgn-bttm-lg" style="width: 100%;">
                    <p class="h2"><span class="safetySignals">No new safety signals (potential safety issues) have been identified</span></p>
                    <p>(one continues to be monitored)</p>
                </div>
            </a>
            <a href="#a3" data-figure="1" class="anchor" style="display: flex; align-items: center;">
                <div class="mrgn-tp-lg mrgn-bttm-lg" style="width: 100%">
                    <p class="h2"><span class="totalDoses">{Total doses administered}</span></p>
                    <p>Total doses administered <!--<span class="nowrap">as of <span class="totalDosesDate"></span></span>--></p>
                </div>
            </a>
            <a href="#a3" data-figure="1" class="anchor">
                <div class="mrgn-tp-lg mrgn-bttm-lg">
                    <p class="h2"><span class="totalAEFIs">{Total adverse events}</span></p>
                    <p>Total adverse event following immunization reports</p>
                    <p class="h2"><small>(<span class="percentageDosesAdminTotal">{Percent non-serious (total)}</span> of all doses administered)</small></p>
                </div>
            </a>
            <a href="#seriousNonSerious" data-figure="1" class="anchor">
                <div class="mrgn-tp-lg mrgn-bttm-lg">
                    <p class="h2"><span class="totalNonseriousAEFIs">{Total non-serious adverse events}</span> <!-- of <span class="totalAEFIs">{Total adverse events}--></span></p>
                    <p>Total adverse event following immunization reports that were non-serious</p>
                    <p class="h2"><small>(<span class="percentageDosesAdminNonSerious">{Percent non-serious (total)}</span> of all doses administered)</small></p>
                </div>
            </a>
            <a href="#seriousNonSerious" data-figure="1" class="anchor">
                <div class="mrgn-tp-lg mrgn-bttm-lg">
                    <p class="h2"><span class="totalSeriousAEFIs">{Total serious adverse events}</span> <!--  of <span class="totalAEFIs">{Total adverse events}</span>--></p>
                    <p>Total adverse event following immunization reports that were serious</p>
                    <p class="h2"><small>(<span class="percentageDosesAdminSerious">{Percent serious (total)}</span> of all doses administered)</small></p>
                </div>
            </a>
             <a href="#a3" data-figure="1" class="anchor">
                <div class="mrgn-tp-lg mrgn-bttm-lg">
                    <p class="h2"><span class="newAEFIs">{New adverse events reported since last report}</span></p>
                    <p>New adverse event following immunization reports since last update</p>
                    <p class="h2"><small>(<span class="newNonSeriousAEFIs">{New non-serious adverse events}</span> new non-serious and <span class="nowrap"><span class="newSeriousAEFIs">{New serious adverse events}</span> new serious</span>)</small></p>
                </div>
            </a>
        </div>
        <ul>
            <li>The benefits of vaccines authorized in Canada continue to outweigh the risks.</li>
            <li>Health Canada, the Public Health Agency of Canada (PHAC), the provinces and territories, and manufacturers continue to closely monitor the safety of COVID-19 vaccines. We’ll respond to any safety issues right away and will inform Canadians about any risks that arise in Canada.</li>
            <li>Of the <strong><span class="totalAEFIs"></span></strong> individual reports (<span style="font-weight: bold;"><span class="percentageDosesAdminTotal"></span> of all doses administered</span>), <strong><span class="totalSeriousAEFIs"></span></strong> were considered serious (<span style="font-weight: bold;"><span class="percentageDosesAdminSerious"></span> of all doses administered</span>).</li>
            <li>Cases of <a href="#noteTTS">thrombosis with thrombocytopenia syndrome</a> following vaccination with AstraZeneca/COVISHIELD COVID-19 vaccine continue to be monitored.</li>
            <li>PHAC and Health Canada are also monitoring international reports (<a href="https://www.who.int/news/item/26-05-2021-gacvs-myocarditis-reported-with-covid-19-mrna-vaccines"><a href="https://www.who.int/news/item/26-05-2021-gacvs-myocarditis-reported-with-covid-19-mrna-vaccines">World Health Organization</a>, <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html">United States Centers for Disease Control and Prevention</a>, <a href="https://www.ema.europa.eu/en/news/covid-19-vaccines-update-ongoing-evaluation-myocarditis-pericarditis">European Medicines Agency</a>,<a href="https://www.gov.il/en/departments/news/01062021-03"> Israel</a>) of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) following vaccination with COVID-19 mRNA vaccines. Based on reports received, Health Canada and PHAC are not seeing higher rates than would normally be expected in the general population. To date, <strong>no clear association has been established between myocarditis/pericarditis and mRNA vaccines</strong>, and to date, no regulatory action has been taken in Canada or internationally. Health Canada, PHAC, and the provincial and territorial health authorities are aware of these cases and will continue to monitor closely. Health Canada is also working closely with the manufacturers and international regulators to review information as it becomes available and will take appropriate action when needed.</li>
            <!--<li id="safetyIssue">In March 2021, there were European reports of rare blood clots associated with low levels of blood platelets (thrombocytopenia). Health Canada, the Public Health Agency of Canada, provincial and territorial public health authorities have been monitoring reports in Canada and the <a href="https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-updated-statement-april-23-2021.html">National Advisory Committee on Immunization</a> have been closely monitoring the emerging evidence, with all organizations taking appropriate action. Following an <a href="https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&linkID=SSR00265">assessment of the evidence</a>, Health Canada updated the <a href="https://covid-vaccine.canada.ca/">product information</a> and issued <a href="https://healthycanadians.gc.ca/recall-alert-rappel-avis/index-eng.php">public advisories</a>. Health Canada will continue to monitor information from the manufacturers and international regulators about this and any other potential safety issues. Provincial public health authorities will continue to update their <a href="https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19/vaccines/how-vaccinated.html">immunization strategies</a> as new evidence arises.</li>-->
            <!--<li>The number of adverse event reports was highest among the <strong><span class="highestAgeGroup"></span> age group</strong>, where age was known.</li>-->
            <!--<li>There were more adverse event reports among <strong><span class="highestSex"></span> than <span class="lowestSex"></span></strong>, where sex was known.</li>-->
        </ul>
        <h3 id="a2">Definitions</h3>
        <details>
            <summary>Adverse Event Following Immunization (adverse event)</summary>
            <p>An adverse event is any untoward medical occurrence which follows immunization. It isn’t necessarily causally related to the usage of the vaccine. The adverse event may be any:</p>
            <ul>
                <li>unfavourable or unintended sign (for example: skin rash)</li>
                <li>abnormal laboratory finding</li>
                <li>symptom or </li>
                <li>disease</li>
            </ul>
            <p style="font-size:15px;">For more information, please refer to the <a href="https://vaccine-safety-training.org/tl_files/vs/pdf/report-of-cioms-who-working-group.pdf">Council for International Organizations of Medical Sciences (CIOMS) and World Health Organization (WHO). Definition and Application of Terms for Vaccine Pharmacovigilance. Report of CIOMS/WHO Working group on Vaccine Pharmacovigilance. Geneva: CIOMS and WHO; 2012 </a></p>
        </details>
        <details>
            <summary>Adverse event report</summary>
            <p>Please note that one adverse event report, which represents one person, may report on more than one symptom (i.e a serious or non serious adverse event following immunization, or AEFI).  </p>
        </details>
        <details>
            <summary>Serious adverse event</summary>
            <p>An event is considered serious if it:</p>
            <ul>
                <li>results in death</li>
                <li>is life-threatening (an event/reaction in which the patient was at real, rather than hypothetical, risk of death at the time of the event/reaction)</li>
                <li>requires in-patient hospitalization or prolongation of existing hospitalization</li>
                <li>results in persistent or significant disability/incapacity, or</li>
                <li>results in a congenital anomaly/birth defect</li>
            </ul>
        </details>
        <details>
            <summary>Medically important event</summary>
            <p>An event which may not be immediately life-threatening but requires intervention to prevent one of the outcomes listed above and may also be considered as serious. This is based on the International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. See:</p>
            <p style="font-size:15px;">International Council on Harmonisation (ICH). Support Documentation. Medical Dictionary for Regulatory Activities. <a href="https://www.meddra.org/how-to-use/support-documentation">https://www.meddra.org/how-to-use/support-documentation</a></p>
        </details>
        <details>
            <summary>Adverse Events of Special Interest (AESI)</summary>
            <p>This is a pre-specified medically significant event that has the potential to be causally associated with a vaccine product. It must be carefully monitored and confirmed by further special studies.</p>
            <span style="font-size:15px;">For more information, please refer to <a href="https://www.who.int/vaccine_safety/committee/Module_AESI.pdf?ua=1">World Health Organization. COVID-19 Vaccines: Safety Surveillance Manual.</a></span>
        </details>
        <details>
            <summary id="safetySummary">Safety signal</summary>
            <p>Information indicating a new and potentially causal association between a vaccine and an event that could affect health. The event is either unknown or incompletely documented. It could also indicate a new aspect of a known association. The primary purpose of vaccine post-market surveillance is to detect safety concerns. These concerns include a possible increase in the severity or frequency of expected adverse events, or one or more unexpected events (i.e., an event that is not consistent with Canadian product information or labelling).</p>
            <span style="font-size:15px;">For more information, please refer to <a href="https://www.who.int/initiatives/the-global-vaccine-safety-initiative/investigation-of-safety-signals">World Health Organization: Investigation of safety signals.</a></span>
        </details>
        <h2 id="howToReport">How to report an adverse event</h2>
        <p>If you experience an adverse event following immunization with a COVID-19 vaccine in Canada, please contact your healthcare provider. Learn more about <a href="https://www.canada.ca/en/public-health/services/immunization/reporting-adverse-events-following-immunization/form.html">reporting adverse events</a>.</p>
        
        <h2 id="a3">Summary of adverse event following immunization reports</h2>
        <p>The information on this page reflects detailed case information data from the Public Health Agency of Canada’s Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) and Health Canada’s Canada Vigilance program. The data may undergo changes as more information about cases becomes available.</p>
        <p>There have been a total of <span class="totalAEFIs" style="font-weight: bold;"></span> reports (<span style="font-weight: bold;"><span class="coveragePer100KTotal"></span> reports per 100,000 doses administered</span>) up to and including <span style="font-weight: bold;" class="dateToShort nowrap"></span>. Of the <span class="totalAEFIs" style="font-weight: bold;"></span> reports, <span class="totalSeriousAEFIs" style="font-weight: bold;"></span> were considered serious (<span style="font-weight: bold;"><span class="coveragePer100KSerious"></span> reports per 100,000 doses administered</span>). While the number of doses administered have increased over time, the rate of serious reports has remained low. The cumulative and weekly number of reports, as well as the weekly report rate, are shown in Figure 1.</p>
        <div id="section1" class="section">
            <div id="figure1div" class="figure">
                <h3>Figure 1.
                    <label for="figure1-dropdown-measure" class="hidden">Choose a measure:</label>
                    <span class="nowrap"><select id="figure1-dropdown-measure" class="dropdown">
                        <option value="weekly">Weekly number</option>
                        <option value="rate">Weekly rate</option>
                        <option value="weekly&rate">Weekly number and rate</option>
                        <option value="total">Cumulative number</option>
                    </select></span>
                    <span style="display:none" class="nowrap"><select id="figure1-dropdown-measure_2" class="dropdown">
                        <option value="number">number</option>
                        <option value="rate">rate</option>
                    </select></span>
                    of COVID-19 vaccine adverse event reports and total doses administered per week up to and including <span class="dateToShort">MMM DD, 2021</span> (n=<span class="totalAEFIs"></span>)
                </h3>
                <span id="note"></span>
                <svg class="chart barVertStacked" id="figure1"></svg>
                <!--<span style="font-size: 13px; font-weight:bold;">Please note: When displaying the total doses administered the amount of AEFI reports may become too small to see.</span>-->
            <span style="font-size: 13px;"><strong>Data note:</strong> The shaded area represents a period of time (lag time) where there may be delays in receiving and processing reporting forms.</span>
            </div>
            <!--<span style="font-size: 18px; font-weight:bold;">Cumulative number of COVID-19 vaccine adverse event reports as of</span>-->
            <details id="figure1aDetails" style="display:block">
				<summary>Figure 1: Text Description</summary>
				<div class="table-responsive">
				<table id="figure1aTable" class="table table-striped table-hover table-bordered figureTable">
				    <caption class="text-left"><!--Total & New--> Number of <!--<span class="vaccine-type2"></span>--> COVID-19 adverse event reports up to and including <span class="dateToShort"></span></span> (n=<span class="totalAEFIs"></span>)</caption>
					<thead>
                        <tr class="bg-primary">
                            <th scope="col">Week report received</th>
                            <th scope="col">Weekly non-serious <span class="nowrap">reports</span></th>
                            <th scope="col">Weekly serious <span class="nowrap">reports</span></th>
                            <th scope="col">Cumulative non-serious <span class="nowrap">reports</span></th>
                            <th scope="col">Cumulative serious <span class="nowrap">reports</span></th>
                            <th scope="col">Cumulative number of doses administered</th>
                            <th scope="col">Weekly number of doses administered</th>
                            <th scope="col">Weekly non-serious report rate*</th>
                            <th scope="col">Weekly serious report rate*</th>
                            <th scope="col">Weekly report rate*</th>
                            <!-- add new in front of column titles-->
                        </tr>
					</thead>
					<tbody></tbody>
					<tfoot></tfoot>	
				</table>
				<span><sup>*</sup>Rate per 100,000 doses administered.</span>
				</div>
			</details>
        </div>
        <div id="section2" class="section">
            <h2 id="a4">Adverse event following immunization reports by vaccine name</h2>
            <p>Figure 2 shows the breakdown of reports by vaccine name. For doses administered by vaccine type, please visit the <a href="https://health-infobase.canada.ca/covid-19/vaccination-coverage/">Vaccination Coverage report</a>. COVID-19 vaccines approved for use in Canada currently include: <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/pfizer-biontech.html">Pfizer-BioNTech</a>, <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/moderna.html">Moderna</a>, <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/astrazeneca.html">AstraZeneca</a>, <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/astrazeneca.html">COVISHIELD (a version of the AstraZeneca vaccine manufactured by the Serum Institute of India and sponsored in Canada by Verity Pharmaceuticals Inc.</a>) and <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/janssen.html">Janssen (Johnson and Johnson)</a>. While the Janssen vaccine has been approved for use in Canada, it has not yet been distributed during this reporting period.<!--Although the number of doses administered is not available by vaccine name, <span class="totalDosesPfizer" style="font-weight: bold;"></span> doses of Pfizer-BioNTech and <span class="totalDosesModerna" style="font-weight: bold;"></span> doses of Moderna have been distributed within Canada.--></p>
            <p>Higher rates of non-serious adverse event reports are observed for each vaccine, with serious report rates continuing to remain low. Generally, reported non-serious adverse events are consistent with information provided in the <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines.html">vaccine product pages.</a></p>
            <h3>Figure 2.
                    <label for="figure2-dropdown-measure" class="hidden">Choose a measure:</label>
                    <span class="nowrap"><select id="figure2-dropdown-measure" class="dropdown">
                        <option value="number">Number</option>
                        <option value="rate">Rate</option>
                    </select></span> of adverse event reports by vaccine name up to and including <span class="dateToShort">MMM DD, 2021</span> (n=6,864)</h3>
            <div id="figure2div" class="figure">
                <svg class="chart barVertStacked" id="figure2"></svg>
            </div>
            <details>
				<summary>Figure 2: Text Description</summary>
				<div class="table-responsive">
				<table id="figure2Table" class="table table-striped table-hover table-bordered figureTable" style="margin-top:40px;">
				    <caption>Number and report rate (per 100,000 doses administered) of adverse event reports by vaccine name up to and including <span class="dateToShort">MMM DD, 2021</span> (n=6,864)</caption>
					<thead>
                        <tr class="bg-primary">
                            <th scope="col">Vaccine name</th>
                            <th scope="col">Non-serious reports</th>
                            <th scope="col">Serious reports</th>
                            <th scope="col">Total reports</th>
                            <th scope="col">Total number of doses administered</th>
                            <th scope="col">Total non-serious report rate*</th>
                            <th scope="col">Total serious report rate*</th>
                            <th scope="col">Total report rate*</th>
                        </tr>
					</thead>
					<tbody></tbody>
					<tfoot></tfoot>	
				</table>
				<span style="font-size: 13px; font-weight:bold;">* Per 100,000 doses administered.</span>
				</div>
			</details>
        </div>
        <div id="a5" class="section">
            <h2 id="ageSex">Adverse event following immunization reports by age and sex</h2>
            <ul>
                <li>The rate of reported adverse events was highest among the <strong>80+ year age group</strong> (34.1 per 100,000 doses administered), followed by those in the 40 to 49 age group (32.0 per 100,000 doses administered).</li>
                <li>The majority of adverse event reports were from female (81.0%) and the rate of reports for <b>females</b> was <b>38.6 per 100,000 doses administered</b>, compared to <b>10.4 per 100,000 doses administered</b> for <b>males</b>. 
                <ul>
                    <li>It is unclear if this is due in part to health care seeking behaviour (e.g. reporting adverse events) or biological differences between females and males.</li>
                </ul>
                <li>The higher proportion and rate of females reporting adverse events has been observed in the <a href="https://www.cdc.gov/mmwr/volumes/70/wr/mm7008e3.htm">United States</a>, the <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00224-3/fulltext#seccestitle130">United Kingdom</a>, and <a href="https://www.medrxiv.org/content/10.1101/2021.03.23.21253433v1">other countries</a>.</li>
                <ul>
                    <li>Health Canada, the Public Health Agency of Canada, provincial and territorial public health authorities will continue to monitor but have not identified this as a safety issue.</li>
                </ul>
            </ul>
            <h3>Figure 3. <span class="nowrap"><select id="figure3-dropdown-measure2" class="dropdown">
                        <option value="number">Number</option>
                        <option value="rate">Rate</option>
                    </select></span> of adverse event reports by 
            <select id="figure3-dropdown-measure" class="dropdown">
                        <option value="ageGroup">age group</option>
                        <option value="both">age group and sex</option>
            </select>
            up to and including <span class="dateToShort">MMM DD, 2021</span> (n=<span class="totalAEFIs"></span>)</h3>
            <div id="figure3div" class="figure">
                <!--<h3>Figure 3. <span class="vaccine-type1"></span> adverse events reported by age and sex, 2018/19 influenza season/vaccination campaign<sup>*</sup> as of <span class="dateToShortAgeSex">MMM DD, 2021</span></h3>-->
                <svg class="chart barGrouped trend" id="figure3"></svg>
                <!--<span style="font-size: 18px; font-weight:bold;">adverse event reports submitted by age and sex</span>-->
                <details id="figure3aDetails">				
    				<summary>Figure 3: Text Description</summary>
					<div class="table-responsive">
    				<table id="figure3Table" class="table table-striped table-hover table-bordered figureTable">
    				    <caption class="text-left">Number and rate (per 100,000 doses administered) of adverse event reports by age group and sex up to and including <span class="dateToShort"></span> (n=<span class="totalAEFIs"></span>)</caption>
    					<thead>
                            <tr class="bg-primary">
                                <th scope="col">Age group</th>
                                <th scope="col">Total</th>
                                <th scope="col">Male</th>
                                <th scope="col">Female</th>
                                <th scope="col">Other</th>
                                <th scope="col">Unknown</th>
                                <th scope="col">Number of doses administered by age group</th>
                                <th scope="col">Number of doses administered to males</th>
                                <th scope="col">Number of doses administered to females</th>
                                <th scope="col">Total number of doses administered<sup>1</sup></th>
                                <th scope="col">Rate by age group</th>
                                <th scope="col">Male rate<sup>2</sup></th>
                                <th scope="col">Female rate<sup>2</sup></th>
                                <th scope="col">Total rate (males and females)<sup>1,2</sup></th>
                            </tr>
    					</thead>
    					<tbody></tbody>
    					<tfoot></tfoot>	
    				</table>
    				<p style="font-weight:bold;">
        				<sup>1</sup> Reports not identified as male or female were removed due to small numbers.<br>
        				<sup>2</sup> Per 100,000 doses administered.<br>
        				<sup>3</sup> Includes two reports of breastfeeding infants following maternal vaccination.  Following medical review, it was determined that there is no relationship between symptoms and potential exposure to vaccine/antibodies in breast milk.
					</p>
					</div>
    			</details>				
            </div>
        </div>
        
        <div id="a6" class="section">
            <h2 id="seriousNonSerious">Serious and non-serious adverse events reported</h2>
            <ul>
                <li>All reports of adverse events following immunization received by Health Canada and PHAC are included in this report, regardless of whether they have been linked to the vaccines. This is because we need to look at all the data available to us so we can detect any early signals of an issue.</li>
                <li>Health Canada, PHAC, the provinces and territories, and manufacturers continue to closely monitor the safety of COVID-19 vaccines. Serious events will be reviewed to determine if there is a new safety signal.</li>
				<li>If a new safety issue is found to be related to immunization, Health Canada will take appropriate action. This could include updating the product information, communicating new risks to Canadians and healthcare providers or changing the recommended use of the product.</li>
				<li>The <span style="font-weight:bold;" class="totalAEFIs"></span> individual reports represent <span style="font-weight:bold;" class="totalAEFIs"></span> people who reported one or more adverse events. Among the <span class='totalAEFIs' style='font-weight:bold;'></span> reports, the most frequently reported adverse events are presented in Figure 4.</li>
                <li>The majority of these adverse events are non-serious. </li>
            </ul>
            <h3>Figure 4.
                <!--<label for="figure5-dropdown-measure" class="hidden">Choose a measure:</label>-->
                <!--<span class="nowrap"><select id="figure5-dropdown-measure" class="dropdown">-->
                <!--    <option value="Total Non-serious AEFI">Non-serious</option>-->
                <!--    <option value="Total Serious AEFI">Serious</option>-->
                <!--</select></span>-->
                Most frequently reported adverse events (serious and non-serious combined) up to and including <span class="dateToShort">MMM DD, 2021</span> (n=<span class="figure4NValue"></span>)<!--find the total n value-->
                </h3>
            <div>
                <button style="content-align:center;" id="figure4Toggle" class="btn btn-success">Show more adverse events</button>
            </div>
            <svg class="chart barHorizStacked" id="figure5"></svg>
            <span style="font-size: 13px; font-weight:bold;">Please note that one report represents one person and may contain information on more than one adverse event.</span>
            <details>
				<summary>Figure 4: Text Description</summary>
				<div class="table-responsive">
				<table id="figure5Table" class="table table-striped table-hover table-bordered figureTable">
				    <caption class="text-left">Most frequently reported adverse events (serious and non-serious combined) up to and including <span class="dateToShort nowrap">MMM DD, 2021</span> (n=<span class="figure4NValue"></span>)</caption>
					<thead>
                        <tr class="bg-primary">
                            <th scope="col">Most frequently reported adverse events</th>
                            <th scope="col">Number of adverse events</th>
                        </tr>
					</thead>
					<tbody></tbody>
					<tfoot></tfoot>	
				</table>
				</div>
			</details>
			<h3>Thrombosis with thrombocytopenia syndrome</h3>
			<ul>
			    <li id="noteTTS"><a href="https://brightoncollaboration.us/thrombosis-with-thrombocytopenia-syndrome-interim-case-definition/">Thrombosis with thrombocytopenia syndrome (TTS)</a> is characterized as blood clotting with low platelet levels. <a href="https://thrombosiscanada.ca/wp-uploads/uploads/2021/04/51.-Vaccine-induced-prothrobotic-immune-thrombcytopenia_26Apr21-Final.pdf">Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), also known as Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT)</a>, is characterized as <abbr title="Thrombosis with thrombocytopenia syndrome">TTS</abbr> that seems to be vaccine-induced due to the laboratory-confirmed presence of platelet factor (PF) 4 antibodies.</li>
                <li>Up to and including <span style="font-weight: bold;" class="dateToShort">May 28, 2021</span>, there were <strong>50 cases of <a href="https://brightoncollaboration.us/thrombosis-with-thrombocytopenia-syndrome-case-finding-definition/">TTS</a></strong> in Canada with reports submitted to PHAC or to Health Canada. Of the <abbr title="Thrombosis with thrombocytopenia syndrome">TTS</abbr> cases:</li>
                <ul>
                    <li>46 cases received COVISHIELD/AstraZeneca vaccines, three received a Pfizer vaccine, and one received a Moderna vaccine.</li>
                    <li>Symptom onset ranged from 1 to 52 days after vaccination.</li>
                    <li>31 were males [median age 56 years (age range 34 to 81 years old)], 18 were females [median age 51 years (age range 44 to 88 years old)], and the age and sex of one was not specified.</li>
                    <li>45 reports following the first vaccine dose, one report following the second vaccine dose; dose for four was not specified</li>
                    <li>31 had laboratory results showing the presence of platelet factor (PF) 4 antibodies, indicating <a href="https://thrombosiscanada.ca/wp-uploads/uploads/2021/04/51.-Vaccine-induced-prothrobotic-immune-thrombcytopenia_26Apr21-Final.pdf">VITT (also known as VIPIT)</a>.</li>
                    <li>Six people died.</li>
                </ul>
            </ul>
            <h3>Myocarditis/pericarditis</h3>
            <ul>
                <li><a href="https://brightoncollaboration.us/myocarditis-case-definition-update/">Myocarditis</a> is inflammation of the heart muscle and pericarditis is inflammation of the lining around the heart.</li>
                <li>Up to and including <span style="font-weight: bold;" class="dateToShort">May 28, 2021</span>, there were 35 cases of myocarditis/pericarditis with reports submitted to PHAC or Health Canada. Of the myocarditis/pericarditis cases:</li>
                <ul>
                    <li>25 cases received Pfizer-BioNTech COVID-19 vaccine, 6 cases received Moderna vaccine, 3 cases received COVISHIELD/AstraZeneca vaccines, and the vaccine name of one was not specified</li>
                    <li>Symptom onset ranged from 5 hours to 94 days</li>
                    <li>19 were females [median age 51 years (age range 20 to 78 years old)] and 16 were males [median age 40 years (age range 29 to 70 years old)].</li>
                    <li>22 reports following the first vaccine dose, 11 report following the second vaccine dose;  dose for two was not specified</li>
                </ul>
                <li>To date, <span style="font-weight: bold;">no clear association has been established between myocarditis/pericarditis and COVID-19 vaccines.</span></li>
            </ul>
            <h3>Deaths</h3>
            <ul>
                <li>Up to and including <span style="font-weight: bold;" class="dateToShort">May 28, 2021</span>, a total of <strong>104 deaths were reported</strong> after the administration of a vaccine. Following medical case review using the <a href="https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf ">WHO-UMC causality assessment categories</a>, it has been determined that: </li> 
                <ul>
                    <li>43 are still under investigation</li>
                    <li>40 of these deaths are unlikely linked to a COVID-19 vaccine</li>
                    <li>15 deaths could not be assessed due to insufficient information.</li>
                    <li>6 deaths followed a diagnosis of TTS <stong>(refer to the Thrombosis with Thrombocytopenia Syndrome bullet above)</stong></li>
                </ul>
            </ul>
            <!--remove display none when graph is needed-->
            <h3 style="display:none">Figure 4. Classification of serious adverse events as of <span class="dateToShort">MMM DD, 2021</span></h3>
            <div style="display:none" id="figure4div" class="figure">
                <svg class="chart barHorizStacked" id="figure4"></svg>
                <span style="font-size: 19px; font-weight:bold;">Note: The reason for seriousness was indicated by the reporter. A report may have more than one reason for seriousness.</span>
                <details>
    				<summary>Figure 4: Text Description</summary>
					<div class="table-responsive">
    				<table id="figure4Table" class="table table-striped table-hover table-bordered figureTable">
    				    <caption>Serious reports by reason for seriousness, up to and including <span class="dateToShort">MMM DD, 2021</span></caption>
    					<thead>
                            <tr class="bg-primary">
                                <th scope="col">Serious adverse events</th>
                                <th scope="col">Number of events</th>
                            </tr>
    					</thead>
    					<tbody></tbody>
    					<tfoot></tfoot>	
    				</table>
					</div>
    			</details>
            </div>
            <h2 id="specialInterest">Adverse events of special interest</h2>
            Adverse events of special interest (AESI) are pre-specified medically significant events that have the potential to be causally associated with a vaccine product. They must be carefully monitored and confirmed by further special studies. <abbr title="Adverse events of special interest">AESI</abbr> can be serious or non-serious and can include:
            <ul>
                <li>Events of interest due to their association with COVID-19 infection.</li>
                <li>Events of interest for vaccines in general (e.g. to the specific vaccine type or adjuvants).</li>
            </ul>
            <p>The list of <abbr title="Adverse events of special interest">AESI</abbr>s below takes into consideration the lists of <abbr title="Adverse events of special interest">AESI</abbr>s from these expert groups, manufacturers and regulatory authorities:</p>
            <ul>
                <li><a href="https://brightoncollaboration.us/covid-19/">Brighton Collaboration</a></li>
                <li><a href="http://www.encepp.eu/encepp/openAttachment/fullProtocol/37296">Vaccine COVID-19 Monitoring Readiness protocol</a></li>
            </ul>
            <p>The <abbr title="Adverse events of special interest">AESI</abbr> list changes based on the evolving safety profile of vaccines.  It is important to recall that  although these adverse events may occur after being immunized with a COVID-19 vaccine in Canada, they are rare and may not necessarily be related to the vaccine.  Health Canada and PHAC review the reports to determine whether the vaccine may have played a role in the occurrence of these events.</p>
            <p>Up to and including <span class="dateToShort"></span>, the most commonly reported <abbr title="Adverse events of special interest">AESI</abbr>s were Bell’s palsy and pulmonary embolism (Table 1).</p>
			<div class="table-responsive">
                <table id="AESITable" class="table table-striped table-hover table-bordered figureTable" style="margin-top:40px;">
				    <caption class="text-left"><span style="font-weight: bold;">Table 1. Reported adverse events of special interest by vaccine type (<span class="nowrap"><select id="AESITable-dropdown-measure" class="dropdown">
                        <option value="TOTAL AESIs">Total</option>
                        <option value="Total Pfizer Events">Pfizer</option>
                        <option value="Total Moderna Events">Moderna</option>
                        <option value="Total COVISHIELD/AstraZeneca Events">COVISHIELD/AstraZeneca</option>
                        <option value="Total Unspecified Events">Unspecified</option>
                    </select></span>) up to and including <span class="dateToShort">April 30, 2021</span> (n=<span class="totalAESI"></span>).</span></caption>
					<thead>
                        <tr id="tableHeader" class="bg-primary">
                            <th scope="col" class="col-md-4"><abbr title="Adverse events of special interest">AESI</abbr> Category</th>
                            <th scope="col" class="col-md-6"><abbr title="Adverse events of special interest">AESI</abbr></th>
                            <th scope="col" class="header3Col">Total</th>
                        </tr>
					</thead>
					<tbody>
					</tbody>
					<tfoot></tfoot>	
				</table>
            </div>
            <p><sup>1</sup> Includes reports meeting levels 1-4 of the <a href="https://brightoncollaboration.us/category/pubs-tools/case-definitions/.">Brighton Collaboration case definition.</a></p>
            <p><sup>2</sup> Includes reports meeting levels 1-3 of the <a href="https://brightoncollaboration.us/category/pubs-tools/case-definitions/.">Brighton Collaboration case definition.</a></p>
            <p><sup>3</sup> COVID-19 vaccines that are currently authorized <b>cannot cause an infection</b> because they do <b>not</b> contain the <b>live virus</b>. While they are all highly effective at preventing severe COVID-19 illness and death, no vaccine is 100% effective, and some COVID-19 cases will still occur. For vaccines that have a two-dose regimen, protection begins 14 days after the first dose, and 7 to 14 days after the second dose.</p>
            <p><b>Please note that one report represents one person and may contain information on more than one adverse event of special interest.
            </b></p>
        </div>
        <h2 id="a7">Data notes</h2>
        <p>The data presented in this report are estimates and may not accurately represent national COVID-19 vaccine adverse events for the following reasons: 
        <ol>
            <li>There may be delays in receiving reporting forms and processing reporting forms which may contribute to variations in the amount of reports presented weekly. These delays may be due to jurisdictions investigating and reviewing each adverse event prior to submitting the information to PHAC. There are also limitations to reporting practices such as underreporting, missing information, and differing adverse event reporting practices accross jurisdictions in Canada. </li>
            <li>Information is collected on individuals for whom an report was submitted, not on the total number of individuals who experience an adverse event as not every adverse event is reported. </li>
            <li>New information contained in this report may not be comprehensive but rather represents preliminary results of data received on a weekly basis.</li>
            <li>Reporting jurisdictions may refer to gender as opposed to sex.</li>
            <li>Information on COVID-19 vaccine doses administered are obtained from provincial and territorial partners or their websites. More details on the <a href="https://health-infobase.canada.ca/covid-19/vaccine-administration/technical-notes.html">number of COVID-19 vaccine doses administered are available</a>.</li>
            <li>The data presented in this report represent combined numbers from both CAEFISS and the Canada Vigilance program. Canada Vigilance receives reports directly from vaccine manufacturers, healthcare professionals and consumers. CAEFISS receives reports from regional public health authorities. Although data from these two surveillance systems are carefully merged together, the individual programs are subject to different reporting requirements and definitions. It is also possible that the weekly report contains duplicate reports.</li>
            <li>The current adverse event reporting results only reflect the population that is currently prioritized for vaccination. For more information on priority vaccination for COVID-19, please see <a href="https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-prioritization-initial-doses-covid-19-vaccines.html">National Advisory Committee on Immunization</a> statement.</li>
            <li>Adverse events of special interest are assessed according to the <a href="https://brightoncollaboration.us/category/pubs-tools/case-definitions/">Brighton Collaboration criteria</a> (if available). For example, anaphylaxis  reports that meet the Brighton Collaboration criteria Level 1-3 are presented as “Anaphylaxis”. All other others reports of anaphylaxis that meet the Brighton Collaboration Level 4-5 are included in the “other allergic reactions” category.</li>
        </ol>
        </p>
        <h2 id="acknowledgements">Acknowledgements</h2>
        <p>This weekly report would not be possible without the collaboration of federal, provincial and territorial public health partners as well as everyone taking part in the COVID-19 vaccination rollout in Canada.</p>
		<p>We would also like to thank each individual who took the time to submit an adverse event report for their contribution to vaccine safety in Canada.</p>
		<h2 id="citation">Suggested citation</h2>
		<p>Public Health Agency of Canada. Canadian COVID-19 vaccination safety report. Ottawa: Public Health Agency of Canada; June 11, 2021. <a href="https://health-infobase.canada.ca/covid-19/vaccine-safety/">https://health-infobase.canada.ca/covid-19/vaccine-safety/</a></p>
		<h2 id="a8">Related links</h2>
		<ul>
			<li><a href="https://www.canada.ca/en/public-health/services/immunization/canadian-adverse-events-following-immunization-surveillance-system-caefiss.html">Canadian Adverse Events Following Immunization and Surveillance System (CAEFISS)</a></li>
			<li><a href="https://www.cps.ca/en/impact">Immunization Monitoring Program ACTive (IMPACT)</a></li>
			<li><a href="https://canvas-covid.ca/">Canadian National Vaccine Safety Network (CANVAS)</a></li>
			<li><a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/canada-vigilance-program.html">Canada Vigilance Program</a></li>
			<!--<li><a href="https://cvp-pcv.hc-sc.gc.ca/arq-rei/index-eng.jsp">Canada Vigilance Online Database</a></li>-->
			<li><a href="https://health-products.canada.ca/dpd-bdpp/index-eng.jsp">Drug Product Database</a></li>
			<li><a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/list-drugs.html">Approved COVID-19 Vaccine list</a></li>
			<li><a href="https://covid-vaccine.canada.ca/">COVID-19 vaccines and treatments portal</a></li>
		    <li><a href="https://health-infobase.canada.ca/covid-19/vaccination-coverage/">COVID-19 vaccination in Canada</a></li>
		</ul>

		<div class="row row-no-gutters mrgn-tp-xl">
        	<div class="col-sm-7 col-lg-6">
            	<section class="gc-pg-hlpfl provisional">
                	<div class="well mrgn-bttm-0">
                    	<form id="gc-pg-hlpfl-frm" action="#" method="post" autocomplete="off">
                        	<input type="hidden" name="institutionopt" value="Health Canada">
                        	<input type="hidden" name="themeopt" value="Health">
                        	<input type="hidden" name="sectionopt" value="Vaccines">
							<input type="hidden" name="language" value="en">
                        	<input type="hidden" name="pageTitle" value="COVID-19 vaccine safety">
                        	<input type="hidden" name="submissionPage" value="https://health-infobase.canada.ca/covid-19/vaccine-safety/">
							<input type="hidden" id="helpful" name="helpful" value="Yes">

							<div class="gc-pg-hlpfl-btn">
								<div class="row row-no-gutters">
									<div class="col-xs-12 col-sm-7 mrgn-tp-sm">
										<h2 class="mrgn-tp-sm h5">Did you find what you were looking for?</h2>
									</div>
									<div class="col-xs-8 col-sm-5 text-right">
										<button id="btnyes" type="submit" value="Yes" class="btn btn-primary">Yes</button>
										<button id="btnno" type="button" class="btn btn-primary mrgn-lft-sm nojs-hide">No</button>
									</div>
								</div>
							</div>
							<p class="h3 hidden nojs-show">If not, tell us why:</p>
							<div class="gc-pg-hlpfl-no nojs-show">
								<fieldset>
									<legend class="h4 mrgn-tp-0 mrgn-bttm-md">What was wrong?</legend>
									<div class="radio">
										<label for="problem1">
											<input name="problem" id="problem1" type="radio" value="The answer I need is missing" data-gc-analytics-wtph-value="The answer I need is missing-La réponse dont j’ai besoin n’est pas là" data-gc-analytics-collect="notPrivate">
											The answer I need is missing
										</label>
									</div>
									<div class="radio">
										<label for="problem2">
											<input name="problem" id="problem2" type="radio" value="The information isn’t clear" data-gc-analytics-wtph-value="The information isn’t clear-L'information n'est pas claire" data-gc-analytics-collect="notPrivate">
											The information isn’t clear
										</label>
									</div>
									<div class="radio">
										<label for="problem3">
											<input name="problem" id="problem3" type="radio" value="I’m not in the right place" data-gc-analytics-wtph-value="I’m not in the right place-Je ne suis pas au bon endroit" data-gc-analytics-collect="notPrivate">
											I’m not in the right place
										</label>
									</div>
									<div class="radio">
										<label for="problem4">
											<input name="problem" id="problem4" type="radio" value="Something is broken or incorrect" data-gc-analytics-wtph-value="Something is broken or incorrect-Quelque chose est brisé ou incorrect" data-gc-analytics-collect="notPrivate">
											Something is broken or incorrect
										</label>
									</div>
									<div class="radio">
										<label for="problem5">
											<input name="problem" id="problem5" type="radio" value="Other reason" data-gc-analytics-wtph-value="Other reason-Autre raison" data-gc-analytics-collect="notPrivate">
											Other reason
										</label>
									</div>
								</fieldset>
								<label for="problem6" class="mrgn-bttm-0">Please provide more details</label>
								<p class="small">
									<strong>(Don’t include any personal information. Note that you will not receive a reply.)</strong>
									<br>
									<span class="small">Maximum 300 characters</span>
								</p>
								<textarea id="problem6" name="details" class="full-width" maxlength="300"></textarea>
								<button type="submit" value="No" class="btn btn-primary mrgn-tp-md mrgn-bttm-sm">Submit</button>
							</div>
						</form>
						<div class="gc-pg-hlpfl-thnk hide">
							<p class="h6 mrgn-tp-sm mrgn-bttm-sm"><span class="far fa-check-circle text-success mrgn-rght-sm" aria-hidden="true"></span> Thank you for your feedback</p>
						</div>
					</div>
				</section>
			</div>
			<div class="col-sm-3 col-sm-offset-1 col-lg-offset-3">
				<div class="wb-share" data-wb-share="{&quot;pnlId&quot;:&quot;pnlShrPg&quot;, &quot;lnkClass&quot;: &quot;btn btn-default btn-block mrgn-tp-md&quot;}"></div>
			</div>
		</div>
    	
        <div class="row pagedetails">
            <div class="datemod col-xs-12 mrgn-tp-lg">
                <dl id="wb-dtmd">
                    <dt>Date modified: </dt>
                    <dd><time class="dateModified" property="dateModified">2021-06-10</time></dd>
                </dl>
            </div>
        </div>
    </main>
    <footer id="wb-info">
        <div class="landscape">
            <nav class="container wb-navcurr">
                <h2 class="wb-inv">About government</h2>
                <ul class="list-unstyled colcount-sm-2 colcount-md-3">
                    <li><a href="https://www.canada.ca/en/contact.html">Contact us</a></li>
                    <li><a href="https://www.canada.ca/en/government/dept.html">Departments and agencies</a></li>
                    <li><a href="https://www.canada.ca/en/government/publicservice.html">Public service and military</a></li>
                    <li><a href="https://www.canada.ca/en/news.html">News</a></li>
                    <li><a href="https://www.canada.ca/en/government/system/laws.html">Treaties, laws and regulations</a></li>
                    <li><a href="https://www.canada.ca/en/transparency/reporting.html">Government-wide reporting</a></li>
                    <li><a href="https://pm.gc.ca/eng">Prime Minister</a></li>
                    <li><a href="https://www.canada.ca/en/government/system.html">How government works</a></li>
                    <li><a href="https://open.canada.ca/en/">Open government</a></li>
                </ul>
            </nav>
        </div>
        <div class="brand">
            <div class="container">
                <div class="row">
                    <nav class="col-md-9 col-lg-10 ftr-urlt-lnk">
                        <h2 class="wb-inv">About this site</h2>
                        <ul>
                            <li><a href="https://www.canada.ca/en/social.html">Social media</a></li>
                            <li><a href="https://www.canada.ca/en/mobile.html">Mobile applications</a></li>
                            <li><a href="https://www1.canada.ca/en/newsite.html">About Canada.ca</a></li>
                            <li><a href="https://www.canada.ca/en/transparency/terms.html">Terms and conditions</a></li>
                            <li><a href="https://www.canada.ca/en/transparency/privacy.html">Privacy</a></li>
                        </ul>
                    </nav>
                    <div class="col-xs-6 visible-sm visible-xs tofpg">
                        <a href="#wb-cont">Top of Page <span class="glyphicon glyphicon-chevron-up"></span></a>
                    </div>
                    <div class="col-xs-6 col-md-3 col-lg-2 text-right">
                        <img src="/src/GCWeb/assets/wmms-blk.svg" alt="Symbol of the Government of Canada">
                    </div>
                </div>
            </div>
        </div>
    </footer>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=fetch%2CPromise"></script>
    <script src="https://cdn.polyfill.io/v3/polyfill.min.js"></script>
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/2.2.4/jquery.js"></script>
    <script src="/src/wet-boew/js/wet-boew.min.js"></script>
    <script src="/src/GCWeb/js/theme.min.js"></script>
    <script src="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/js/bootstrap.min.js" integrity="sha384-JjSmVgyd0p3pXB1rRibZUAYoIIy6OrQ6VrjIEaFf/nJGzIxFDsf4x0xIM+B07jRM" crossorigin="anonymous"></script>
    <script src="https://d3js.org/d3.v5.min.js"></script>
    <script src="https://cdn.jsdelivr.net/npm/d3-interpolate-path@2.0.0/build/d3-interpolate-path.min.js"></script>
    <script src="https://d3js.org/topojson.v2.min.js"></script>
    <script src="/src/js/polylabel.js"></script>
    <script src="/src/js/d3-array.v2.min.js"></script>
    <script src="/src/js/vaccine-safety/vaccine.js"></script>
    <script src="/src/js/survey.js"></script>
	<script>
       $(document).on("wb-ready.wb", function() {
           $("#btnno").click(function(e) {
               $(".gc-pg-hlpfl-no").removeClass("nojs-show");
               $(".gc-pg-hlpfl-btn").addClass("hide");
               $("#helpful").val("No");
           });
           $("#gc-pg-hlpfl-frm").submit(function(e) {
               e.preventDefault();
               $(".gc-pg-hlpfl-thnk").removeClass("hide");
               $("#gc-pg-hlpfl-frm").addClass("hide nojs-show");
               $.ajax({
                   url: 'https://pagesuccessemailqueue.azurewebsites.net/api/QueueProblemForm',
                   type: 'POST',
                   dataType: 'text',
                   data: $('form#gc-pg-hlpfl-frm').serialize(),
                   success: function(data) {},
                   error: function(xhr, status, err) {
                       console.log(xhr.responseText);
                   }
               });
           });
       });
   </script>

</body>
</html>